MedTrace Logo

Comparison of PRF and Corticosteroids in Impacted Third Molar Surgery

NCT07742826 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-03

No results posted yet for this study

Summary

This prospective, randomized interventional study aims to compare the postoperative effects of standard treatment (control), platelet-rich fibrin (PRF), and PRF combined with corticosteroid treatment in patients undergoing impacted mandibular third molar surgery. A total of 60 participants will be randomly assigned to one of three treatment groups according to the study protocol. Postoperative pain, facial swelling, and trismus will be evaluated on postoperative days 1, 2, 3, and 7. The findings of this study are expected to provide evidence regarding the effectiveness of PRF alone and PRF combined with corticosteroid treatment in reducing postoperative complications following impacted mandibular third molar surgery.

Conditions

  • Impacted Mandibular Third Molar Extraction
  • Impacted Lower Third Molar
  • Impacted Wisdom Tooth

Interventions

BIOLOGICAL

Platelet-rich fibrin (PRF)

Autologous platelet-rich fibrin (PRF) prepared from the participant's venous blood by centrifugation at 3000 rpm for 10 minutes, and then placed into the extraction socket immediately after impacted mandibular third molar surgery.

DRUG

Dexamethasone

Dexamethasone (8 mg/2 mL) administered as a single intramuscular injection immediately after impacted mandibular third molar surgery in addition to platelet-rich fibrin (PRF), according to the study protocol.

DRUG

Amoxicillin/Clavulanic Acid

Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.

DRUG

Paracetamol

Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.

DRUG

Chlorhexidine

Chlorhexidine mouthwash administered postoperatively according to the study protocol.

Sponsors & Collaborators

  • Final International University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-03
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Cyprus

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07742826 on ClinicalTrials.gov